{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:05:14Z","timestamp":1790791514781,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004896","name":"Eisai Incorporated","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004896","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ygyno.2023.01.003","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T17:51:53Z","timestamp":1675792313000},"page":"300-308","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer"],"prefix":"10.1016","volume":"170","author":[{"given":"Thomas J.","family":"Herzog","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Pignata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharad A.","family":"Ghamande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Jes\u00fas","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Vulsteke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah K.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalid","family":"Sehouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Gabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley J.","family":"Monk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.","family":"Arranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimio","family":"Ushijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabbie","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Zamagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Wenham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antionio","family":"Gonz\u00e1lez-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Slomovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Ramsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnansu S.","family":"Tewari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan C.","family":"Weil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignace B.","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2023.01.003_bb0005","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10555-014-9539-8","article-title":"Role of the folate receptor in ovarian cancer treatment: evidence mechanism, and clinical implications","volume":"34","author":"Vergote","year":"2015","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ygyno.2023.01.003_bb0010","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ab.2004.12.026","article-title":"Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay","volume":"338","author":"Parker","year":"2005","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ygyno.2023.01.003_bb0015","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/(SICI)1097-0215(19970422)74:2<193::AID-IJC10>3.0.CO;2-F","article-title":"Overexpression of folate binding protein in ovarian cancers","volume":"74","author":"Toffoli","year":"1997","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2023.01.003_bb0020","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/PGP.0b013e3182774562","article-title":"Expression of folate receptor-\u03b1 (FRA) in gynecologic malignancies and its relationship to the tumor type","volume":"32","author":"O\u2019Shannessy","year":"2013","journal-title":"Int. J. Gynecol. Pathol."},{"key":"10.1016\/j.ygyno.2023.01.003_bb0025","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.molonc.2011.11.010","article-title":"Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response","volume":"6","author":"Chen","year":"2012","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ygyno.2023.01.003_bb0030","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/(SICI)1097-0215(19980417)79:2<121::AID-IJC4>3.0.CO;2-V","article-title":"Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer","volume":"79","author":"Toffoli","year":"1998","journal-title":"Int J Cancer (Pred Oncol)"},{"key":"10.1016\/j.ygyno.2023.01.003_bb0035","first-page":"6","article-title":"Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha","volume":"7","author":"Ebel","year":"2007","journal-title":"Cancer Immun."},{"key":"10.1016\/j.ygyno.2023.01.003_bb0040","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ygyno.2013.03.002","article-title":"Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer","volume":"129","author":"Armstrong","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"19","key":"10.1016\/j.ygyno.2023.01.003_bb0045","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1200\/JCO.2015.63.2596","article-title":"A randomized, double-blind, placebo-controlled, phase III study to assess efficacy and safety of weekly farletuzumab in combination with CARBOplatin and taxane in patients with ovarian cancer in first platinum-sensitive relapse","volume":"34","author":"Vergote","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.01.003_bb0050","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1634\/theoncologist.2-1-6","article-title":"The role of CA-125 in the management of ovarian cancer","volume":"2","author":"Markman","year":"1997","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2023.01.003_bb0055","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1200\/JCO.2005.04.7373","article-title":"Pretreatment CA-125 and risk of relapse in advanced ovarian cancer","volume":"24","author":"Markman","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.01.003_bb0060","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/1476-4598-13-129","article-title":"MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress","volume":"13","author":"Felder","year":"2014","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ygyno.2023.01.003_bb0065","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1476-4598-9-11","article-title":"MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells","volume":"9","author":"Gubbels","year":"2010","journal-title":"Mol. Cancer"},{"issue":"32","key":"10.1016\/j.ygyno.2023.01.003_bb0070","doi-asserted-by":"crossref","first-page":"52045","DOI":"10.18632\/oncotarget.19090","article-title":"Tumor antigen CA125 suppresses antibody-dependent cellular cytotoxicity (ADCC) via direct antibody binding and suppressed fc-y receptor engagement","volume":"8","author":"Kline","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.ygyno.2023.01.003_bb0075","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/IGC.0b013e3181d3caa8","article-title":"European network of Gynaecological oncological trial Groups\u2019 requirements for trials between academic groups and pharmaceutical companies","volume":"20","author":"Vergote","year":"2010","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2023.01.003_bb0080","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2023.01.003_bb0085","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ygyno.2009.11.033","article-title":"Achievements and unmet needs in the management of advanced ovarian cancer","volume":"117","author":"Guarneri","year":"2010","journal-title":"Gynecol. Oncol."},{"issue":"Suppl. 7","key":"10.1016\/j.ygyno.2023.01.003_bb0090","article-title":"Optimal treatment for relapsing ovarian cancer","volume":"21","author":"Ledermann","year":"2010","journal-title":"Ann Oncol Oct"},{"issue":"6","key":"10.1016\/j.ygyno.2023.01.003_bb0095","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG oncology\/gynecologic oncology group study GOG-0213): a multicentre, open-label, randomised phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ygyno.2023.01.003_bb0100","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.6004\/jnccn.2012.0140","article-title":"Ovarian cancer, version 3.2012","volume":"10","author":"Morgan","year":"2012","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"1","key":"10.1016\/j.ygyno.2023.01.003_bb0105","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2023.01.003_bb0110","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4161\/cbt.26106","article-title":"The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity","volume":"14","author":"Lin","year":"2013","journal-title":"Cancer Biol Ther"},{"issue":"20","key":"10.1016\/j.ygyno.2023.01.003_bb0115","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","article-title":"Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse","volume":"28","author":"Pujade-Lauraine","year":"2010","journal-title":"J Clin Onc"},{"issue":"6","key":"10.1016\/j.ygyno.2023.01.003_bb0120","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","article-title":"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I","volume":"32","author":"Moore","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2023.01.003_bb0125","series-title":"Abstract LBA 4","article-title":"Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: Results from the SORAYA study. Presented at SGO 2022; March 18\u201321","author":"Matulonis","year":"2022"},{"key":"10.1016\/j.ygyno.2023.01.003_bb0130","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.2147\/OTT.S98242","article-title":"Profile of farletuzumab and its potential in the treatment of solid tumors","volume":"9","author":"Sato","year":"2016","journal-title":"Onco Targets Ther"},{"issue":"2","key":"10.1016\/j.ygyno.2023.01.003_bb0135","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2217\/fon-2017-0379","article-title":"A review of mirvetuzimab soravtansine in the treatment of platinum-resistant ovarian cancer","volume":"14","author":"Moore","year":"2018","journal-title":"Future Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2023.01.003_bb0140","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1158\/1535-7163.MCT-17-1215","article-title":"MORAb-202, an antibody-drug conjugate utilizing humanized anti-human FR\u03b1 farletuzumab and the microtubule-targeting agent eribulin, has potent antitumor activity","volume":"17","author":"Cheng","year":"2018","journal-title":"Mol. Cancer Ther."},{"issue":"14","key":"10.1016\/j.ygyno.2023.01.003_bb0145","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1158\/1078-0432.CCR-20-4740","article-title":"First-in-human phase 1 study of MORAb-202, an antibody-drug conjugate comprising farletuzumab linked to eribulin mesylate, in patients with folate receptor-\u03b1-positive advanced solid tumors","volume":"27","author":"Shimizu","year":"2021","journal-title":"Clin. Cancer Res."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825823000033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825823000033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:50:10Z","timestamp":1715820610000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825823000033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":29,"alternative-id":["S0090825823000033"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.01.003","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}